EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Clinical Usefulness of Cancer Markers in Primary Breast Cancer

A. Verring, A. Clouth, P. Ziolkowski, G. M. Oremek

ISRN Pathology · 2011

DOI: 10.5402/2011/817618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Pathology, 2011. Verfasst von A. Verring und 3 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths. The results were obtained using a specific immunoassay and using producers' cut offs. The following sensitivity and specificity of markers were found: CA 549 (sen.: 40%/spec.: 90%), MSA (sen.: 22%/spec.: 96%), and CA 15-3 (sen.: 33%/spec.: 86%). Ideal cut offs were defined with ROC curves. A significant correlation was found between CA 549, MSA, and CA 15-3. The combination of markers does not improve the clinical usefulness to identify only breast cancer. Serum tumor markers are abnormally elevated in patients with breast cancer. CA 549, MSA, CA 15-3 are useful clinical markers, good indicators of disease extent, and may have important prognostic value. This study demonstrates the role of the tumor markers in breast cancer.

Zitieren

APA

Verring, A., Clouth, A., Ziolkowski, P., & Oremek, G. M. (2011). Clinical Usefulness of Cancer Markers in Primary Breast Cancer. ISRN Pathology. https://doi.org/10.5402/2011/817618

Vancouver

Verring A, Clouth A, Ziolkowski P, Oremek GM. Clinical Usefulness of Cancer Markers in Primary Breast Cancer. ISRN Pathology. 2011. doi:10.5402/2011/817618

BibTeX
@article{Verring2011,
  author = {Verring, A. and Clouth, A. and Ziolkowski, P. and Oremek, G. M.},
  title = {Clinical Usefulness of Cancer Markers in Primary Breast Cancer},
  journal = {ISRN Pathology},
  year = {2011},
  doi = {10.5402/2011/817618}
}
Kostenlos starten →